---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-233432"
form_type: "8-K"
ticker: "LYRA"
cik: "0001327273"
company_name: "Lyra Therapeutics, Inc."
filed_at: "2023-09-12T23:59:59+00:00"
generated_at: "2026-06-10T20:34:25.342531+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "low"
source: SEC EDGAR
---

# Lyra posts slide deck with BEACON Phase 2 topline results for LYR-220 in CRS

## Summary
- LYR-220 evaluated in Phase 2 BEACON study for chronic rhinosinusitis with/without polyps in patients with prior ethmoidectomy.
- Topline results posted as slide deck on Lyra investor website on Sept 12, 2023; no specific data included in this 8-K text.
- Study identifier NCT05035654 on clinicaltrials.gov; two-part, patient-blinded, randomized trial.
- No financial impact or guidance changes announced; materiality depends on the actual results not seen here.

## SEC filing metadata
- accession: 0001193125-23-233432
- form_type: 8-K
- ticker: LYRA
- cik: 0001327273
- company_name: Lyra Therapeutics, Inc.
- filed_at: 2023-09-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1327273/000119312523233432/0001193125-23-233432-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1327273/000119312523233432/d536466d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-233432
- JSON: https://secwatch.observer/filing/0001193125-23-233432.json
- Plain text: https://secwatch.observer/filing/0001193125-23-233432.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.